MeSH term
Frequency | Condition_Probility | Humans | 609 | 0.0 |
Adult | 233 | 0.0 |
Aged | 107 | 0.0 |
Aged, 80 and over | 21 | 0.0 |
Alleles | 32 | 0.0 |
Apolipoproteins E/blood/genetics | 2 | 12.0 |
Cardiovascular Diseases/blood/*genetics | 3 | 25.0 |
DNA/genetics | 4 | 0.0 |
Family Health | 2 | 0.0 |
Female | 261 | 0.0 |
Gene Frequency | 28 | 0.0 |
Genotype | 62 | 0.0 |
*Glycoproteins | 502 | 58.0 |
Male | 336 | 0.0 |
Middle Aged | 231 | 0.0 |
Polymorphism, Genetic | 27 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 140 | 0.0 |
Risk Factors | 32 | 0.0 |
Carrier Proteins/*genetics | 88 | 7.0 |
DNA Mutational Analysis | 4 | 0.0 |
Lipoproteins, LDL/*chemistry | 3 | 14.0 |
Mutation/*genetics | 3 | 0.0 |
Particle Size | 28 | 10.0 |
Polymerase Chain Reaction | 35 | 0.0 |
Polymorphism, Restriction Fragment Length | 12 | 0.0 |
Amino Acid Sequence | 20 | 0.0 |
Base Sequence | 48 | 0.0 |
Carrier Proteins/chemistry/*genetics | 3 | 4.0 |
Japan/ethnology | 4 | 5.0 |
Lipoproteins, HDL Cholesterol/blood | 74 | 10.0 |
Molecular Sequence Data | 48 | 0.0 |
Adolescent | 26 | 0.0 |
Analysis of Variance | 23 | 1.0 |
Anthropometry | 2 | 0.0 |
Apoproteins/blood | 2 | 10.0 |
Cholesterol, Dietary/*administration & dosage | 3 | 27.0 |
Coronary Disease/*blood | 2 | 3.0 |
Cross-Over Studies | 10 | 1.0 |
Ethnic Groups | 2 | 0.0 |
Lipids/blood | 47 | 7.0 |
Lipoproteins, HDL Cholesterol/*blood | 58 | 26.0 |
Lipoproteins, LDL Cholesterol/*blood | 7 | 8.0 |
Time Factors | 21 | 0.0 |
Animals | 164 | 0.0 |
Carrier Proteins/genetics/*metabolism | 10 | 2.0 |
Comparative Study | 83 | 0.0 |
Kinetics | 48 | 0.0 |
Lipoproteins/*blood | 39 | 6.0 |
Mice | 76 | 0.0 |
Mice, Inbred C57BL | 22 | 0.0 |
Mice, Knockout | 9 | 0.0 |
Mice, Transgenic | 48 | 1.0 |
Research Support, Non-U.S. Gov't | 372 | 0.0 |
Apolipoproteins B/blood | 23 | 9.0 |
Carrier Proteins/*blood | 107 | 44.0 |
Hypercholesterolemia/*blood | 4 | 19.0 |
Japan | 14 | 0.0 |
Lipoproteins, HDL/*blood | 46 | 23.0 |
Lipoproteins, LDL Cholesterol/blood | 44 | 8.0 |
Carrier Proteins/genetics | 10 | 2.0 |
Cholelithiasis/*genetics | 2 | 66.0 |
*Cholesterol | 2 | 22.0 |
Chromosome Mapping | 4 | 0.0 |
Cytochrome P-450 Enzyme System/genetics | 3 | 2.0 |
English Abstract | 26 | 0.0 |
Genetics, Population | 3 | 0.0 |
Mice, Inbred Strains | 3 | 0.0 |
*Phospholipid Transfer Proteins | 39 | 24.0 |
Polymorphism, Genetic/genetics | 3 | 0.0 |
Quantitative Trait, Heritable | 2 | 3.0 |
Variation (Genetics) | 9 | 0.0 |
Apolipoprotein A-I/blood | 18 | 16.0 |
Arteriosclerosis/blood | 2 | 8.0 |
Body Mass Index | 17 | 1.0 |
Child | 13 | 0.0 |
Child, Preschool | 7 | 0.0 |
Cholesterol/blood | 53 | 4.0 |
Insulin/blood | 4 | 0.0 |
Obesity/*blood | 2 | 2.0 |
Reference Values | 41 | 0.0 |
Triglycerides/blood | 85 | 6.0 |
*Diet | 5 | 2.0 |
Dietary Fats/*administration & dosage | 7 | 8.0 |
Genome | 2 | 0.0 |
Linkage (Genetics) | 5 | 0.0 |
Carrier Proteins/analysis/*genetics | 3 | 15.0 |
Case-Control Studies | 16 | 0.0 |
Cohort Studies | 16 | 0.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Incidence | 3 | 0.0 |
*Polymorphism, Genetic | 38 | 0.0 |
Probability | 7 | 1.0 |
Carrier Proteins/*genetics/metabolism | 12 | 4.0 |
Glycoproteins/*genetics/metabolism | 2 | 5.0 |
*Promoter Regions (Genetics) | 9 | 0.0 |
Sequence Alignment | 6 | 0.0 |
Apolipoproteins E/genetics | 8 | 2.0 |
Body Composition | 3 | 1.0 |
Body Weight/physiology | 2 | 2.0 |
Diet, Fat-Restricted | 2 | 10.0 |
Exercise/*physiology | 3 | 0.0 |
Lipoprotein Lipase/genetics | 3 | 10.0 |
Magnetic Resonance Spectroscopy | 3 | 0.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Lipids/*metabolism | 6 | 2.0 |
Alcohol Drinking/epidemiology | 3 | 15.0 |
Apolipoproteins/genetics | 4 | 17.0 |
Japan/epidemiology | 5 | 1.0 |
Linear Models | 3 | 0.0 |
Lipids | 2 | 10.0 |
Rural Population | 2 | 2.0 |
Smoking/epidemiology | 3 | 4.0 |
Taq Polymerase | 2 | 5.0 |
Lipoproteins/metabolism | 11 | 10.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Carrier Proteins/genetics/metabolism | 2 | 1.0 |
*Haplotypes | 2 | 0.0 |
Linkage Disequilibrium | 7 | 0.0 |
Lipoproteins, HDL/blood/*metabolism | 2 | 18.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/genetics/metabolism | 2 | 40.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Structure-Activity Relationship | 16 | 0.0 |
*Variation (Genetics) | 9 | 0.0 |
Fasting/blood | 4 | 7.0 |
Polymorphism, Genetic/*physiology | 3 | 4.0 |
Apolipoproteins/blood | 31 | 13.0 |
Carrier Proteins/*antagonists & inhibitors | 13 | 56.0 |
Dose-Response Relationship, Drug | 14 | 0.0 |
Double-Blind Method | 14 | 0.0 |
Lipoproteins/blood | 29 | 7.0 |
Precipitation | 2 | 1.0 |
Sensitivity and Specificity | 14 | 0.0 |
Ultracentrifugation | 7 | 3.0 |
Biological Transport | 43 | 3.0 |
Cardiovascular Diseases/prevention & control | 4 | 30.0 |
Carrier Proteins/blood | 38 | 36.0 |
Cholesterol Esters/*blood | 45 | 54.0 |
*Estrogen Replacement Therapy | 2 | 1.0 |
Lipoprotein Lipase/blood | 7 | 8.0 |
Lipoproteins, LDL/blood | 20 | 8.0 |
Membrane Proteins/blood | 7 | 17.0 |
*Postmenopause | 2 | 3.0 |
Apolipoproteins A/*genetics | 2 | 4.0 |
Apolipoproteins E/*genetics | 8 | 0.0 |
Diet | 11 | 3.0 |
Lipoproteins, HDL/blood | 24 | 9.0 |
*Membrane Proteins | 5 | 0.0 |
*Receptors, Lipoprotein | 2 | 1.0 |
Lipoproteins, HDL/genetics/*metabolism | 2 | 28.0 |
Liver/*enzymology | 9 | 1.0 |
Regression Analysis | 12 | 0.0 |
Triglycerides/metabolism | 19 | 11.0 |
Carrier Proteins/*blood/*genetics | 6 | 60.0 |
Mutation | 20 | 0.0 |
Myocardial Infarction/blood/*genetics | 2 | 15.0 |
Genetic Predisposition to Disease | 7 | 0.0 |
Multivariate Analysis | 8 | 0.0 |
Myocardial Infarction/epidemiology/*genetics | 2 | 15.0 |
Prospective Studies | 8 | 0.0 |
Risk Assessment | 4 | 0.0 |
Asian Continental Ancestry Group/*genetics | 5 | 1.0 |
Gene Expression Regulation | 13 | 0.0 |
Promoter Regions (Genetics) | 9 | 0.0 |
Lipoproteins, HDL Cholesterol/*blood/*genetics | 3 | 60.0 |
Sampling Studies | 2 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Coronary Disease/blood/*genetics | 2 | 10.0 |
Glycoproteins/*genetics | 4 | 2.0 |
Lipids/*blood | 29 | 5.0 |
Apolipoproteins/blood/metabolism | 3 | 75.0 |
Biological Transport, Active | 4 | 2.0 |
Carrier Proteins/metabolism | 20 | 2.0 |
Cholesterol/*blood | 15 | 6.0 |
Glycoproteins/metabolism | 5 | 3.0 |
Lipoproteins/blood/metabolism | 3 | 17.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/metabolism | 14 | 25.0 |
Physical Fitness/*physiology | 2 | 5.0 |
Rats | 10 | 0.0 |
Tumor Cells, Cultured | 9 | 0.0 |
Chromatography, Gel | 9 | 1.0 |
Electrophoresis, Agar Gel | 5 | 0.0 |
Lipoproteins, HDL/*metabolism | 29 | 24.0 |
Pregnancy | 2 | 0.0 |
Sterol O-Acyltransferase/blood | 3 | 42.0 |
Antilipemic Agents/*therapeutic use | 5 | 6.0 |
Hypertriglyceridemia/blood/*drug therapy | 2 | 50.0 |
Insulin Resistance/*physiology | 2 | 2.0 |
Lipoproteins, HDL Cholesterol/*blood/drug effects | 2 | 66.0 |
Apolipoprotein A-I/*genetics | 4 | 13.0 |
Receptors, LDL/*genetics | 3 | 1.0 |
Cholesterol Esters/metabolism | 29 | 26.0 |
*Mutation | 16 | 0.0 |
*Polymorphism, Single Nucleotide | 4 | 0.0 |
Blood Glucose/metabolism | 4 | 0.0 |
Hypoglycemic Agents/therapeutic use | 2 | 4.0 |
Chi-Square Distribution | 3 | 0.0 |
Korea | 3 | 1.0 |
Anticholesteremic Agents/therapeutic use | 3 | 9.0 |
Apolipoproteins B/metabolism | 6 | 6.0 |
Cholesterol/metabolism | 14 | 4.0 |
Clinical Trials | 4 | 0.0 |
Hyperlipidemia/*drug therapy | 4 | 13.0 |
Blotting, Northern | 4 | 0.0 |
DNA Primers | 6 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
Insulin/*pharmacology | 4 | 1.0 |
Lipoproteins/*metabolism | 12 | 7.0 |
RNA, Messenger/genetics | 8 | 0.0 |
Age Distribution | 2 | 0.0 |
Prevalence | 10 | 0.0 |
Sex Distribution | 4 | 1.0 |
Aging/metabolism | 2 | 1.0 |
China | 3 | 0.0 |
Estradiol/blood | 2 | 0.0 |
Cholesterol Esters/blood/*metabolism | 6 | 75.0 |
Lipase/blood | 4 | 5.0 |
Liver/enzymology | 12 | 2.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/blood | 25 | 34.0 |
Apolipoproteins C/genetics | 3 | 8.0 |
Codon | 4 | 0.0 |
Sex Characteristics | 8 | 1.0 |
Smoking | 5 | 1.0 |
Homozygote | 14 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
COS Cells | 3 | 0.0 |
Cells, Cultured | 15 | 0.0 |
Cholesterol/*metabolism | 19 | 7.0 |
Immunohistochemistry | 3 | 0.0 |
Lipoproteins, HDL/metabolism | 16 | 15.0 |
Macrophages/metabolism | 4 | 1.0 |
Transfection | 15 | 0.0 |
Cats | 2 | 0.0 |
Adipocytes/metabolism | 2 | 4.0 |
Cell Line | 18 | 0.0 |
Lipoproteins, VLDL/metabolism | 10 | 9.0 |
Triglycerides/*blood | 16 | 4.0 |
Disease Models, Animal | 4 | 0.0 |
Liver/metabolism | 14 | 1.0 |
*Receptors, Immunologic | 2 | 1.0 |
Up-Regulation | 4 | 0.0 |
Carrier Proteins/blood/*genetics | 18 | 54.0 |
Heterozygote | 15 | 0.0 |
Binding Sites | 8 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Protein Binding | 12 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Carrier Proteins/*genetics/pharmacology | 2 | 50.0 |
Carrier Proteins/*blood/drug effects | 3 | 60.0 |
Lipoprotein(a)/blood | 2 | 3.0 |
Cholesterol Esters/*chemistry/metabolism | 2 | 100.0 |
Dogs | 3 | 0.0 |
Lipoproteins, HDL/*chemistry/metabolism | 3 | 60.0 |
Models, Biological | 6 | 0.0 |
Models, Chemical | 4 | 1.0 |
Phosphatidylcholines/chemistry | 2 | 10.0 |
Species Specificity | 8 | 0.0 |
Promoter Regions (Genetics)/*genetics | 4 | 0.0 |
Sequence Analysis, DNA | 5 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Weight Loss | 4 | 2.0 |
Arteriosclerosis/*etiology | 3 | 7.0 |
Arteriosclerosis/*genetics | 2 | 7.0 |
Carotid Artery Diseases/*genetics | 2 | 66.0 |
Haplotypes | 4 | 0.0 |
Polymorphism, Single-Stranded Conformational | 5 | 0.0 |
Carrier Proteins/blood/*metabolism | 6 | 28.0 |
Exercise | 2 | 1.0 |
Glucose Clamp Technique | 4 | 3.0 |
Insulin Resistance | 4 | 2.0 |
Apolipoproteins/*genetics | 5 | 7.0 |
Arteriosclerosis/etiology/*genetics | 2 | 50.0 |
Postprandial Period | 7 | 7.0 |
Amino Acid Substitution | 3 | 0.0 |
Carrier Proteins/*blood/genetics | 9 | 47.0 |
*Renal Dialysis | 5 | 1.0 |
Carrier Proteins/genetics/*physiology | 5 | 5.0 |
Apolipoproteins/*blood | 9 | 5.0 |
Arteriosclerosis/blood/etiology | 2 | 14.0 |
Lipoproteins, LDL/*blood | 13 | 8.0 |
Cholesterol Esters/blood/metabolism | 4 | 57.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 17 | 0.0 |
Hyperlipoproteinemia/blood/*genetics | 6 | 60.0 |
*Point Mutation | 5 | 0.0 |
Transcription Factors/metabolism | 5 | 0.0 |
Transcription, Genetic | 5 | 0.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
Docosahexaenoic Acids/pharmacology | 2 | 22.0 |
Fatty Acids/metabolism | 2 | 1.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
RNA, Messenger/analysis | 4 | 0.0 |
RNA, Messenger/metabolism | 12 | 0.0 |
Tissue Distribution | 8 | 0.0 |
Tunica Intima/pathology | 2 | 7.0 |
Carrier Proteins/*biosynthesis/genetics | 3 | 5.0 |
Hypercholesterolemia/metabolism | 2 | 40.0 |
Cholesterol 7-alpha-Hydroxylase/genetics | 2 | 25.0 |
Receptors, Cytoplasmic and Nuclear/*metabolism | 2 | 1.0 |
Sterols/*pharmacology | 2 | 66.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Cholesterol Esters/*metabolism | 56 | 63.0 |
Coronary Disease/genetics | 6 | 17.0 |
Deoxyribonucleases, Type II Site-Specific | 2 | 0.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
Aorta/pathology | 2 | 5.0 |
Chylomicrons/blood | 3 | 7.0 |
Diet, Atherogenic | 2 | 6.0 |
Gene Expression | 11 | 0.0 |
Lipoproteins, VLDL Cholesterol/blood | 8 | 12.0 |
Mice, Transgenic/*blood | 2 | 100.0 |
Lipase/*genetics | 4 | 11.0 |
Chromatography, High Pressure Liquid | 7 | 0.0 |
Lipoproteins, VLDL/blood | 17 | 7.0 |
Tritium | 4 | 1.0 |
Apolipoprotein A-II/blood | 7 | 36.0 |
Cardiovascular Diseases/etiology | 2 | 4.0 |
Triglycerides/blood/metabolism | 2 | 9.0 |
Apolipoproteins C/*genetics | 2 | 2.0 |
Cholesterol Esters/genetics | 3 | 100.0 |
Hypercholesterolemia/*genetics | 2 | 11.0 |
Lipoprotein Lipase/*genetics | 4 | 2.0 |
Hyperlipidemia/metabolism | 3 | 33.0 |
Models, Molecular | 6 | 0.0 |
Phospholipids/metabolism | 3 | 1.0 |
Protein Conformation | 9 | 0.0 |
Cholesterol Esters/blood | 38 | 31.0 |
Dietary Fats/pharmacology | 3 | 8.0 |
*Exercise | 2 | 1.0 |
Fatty Acids/*administration & dosage | 3 | 30.0 |
*Postprandial Period | 5 | 17.0 |
Carrier Proteins/*metabolism | 42 | 5.0 |
Emulsions | 6 | 8.0 |
Lipoproteins/chemistry | 3 | 25.0 |
Lipoproteins, HDL/*chemistry | 6 | 35.0 |
Rats, Wistar | 2 | 0.0 |
Apolipoprotein A-II/*metabolism | 3 | 27.0 |
Chromatography, Liquid | 3 | 2.0 |
Lipoproteins, LDL/*metabolism | 8 | 4.0 |
Oxidation-Reduction | 5 | 0.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*blood | 14 | 12.0 |
Fasting | 6 | 1.0 |
Lipoprotein Lipase/*metabolism | 5 | 2.0 |
*Genetic Predisposition to Disease | 5 | 0.0 |
Lipids/*blood/metabolism | 2 | 16.0 |
*Neoplasm Proteins | 2 | 0.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
Arteriosclerosis/genetics/metabolism/*prevention & control | 2 | 66.0 |
Lipoproteins, HDL Cholesterol/metabolism | 10 | 20.0 |
Lipoproteins, LDL Cholesterol/*metabolism | 2 | 10.0 |
Rabbits | 26 | 0.0 |
CHO Cells | 7 | 0.0 |
Carrier Proteins/*antagonists & inhibitors/metabolism | 2 | 20.0 |
Disulfides/chemistry/pharmacology | 2 | 100.0 |
Drug Synergism | 2 | 0.0 |
Hamsters | 23 | 0.0 |
Stereoisomerism | 5 | 1.0 |
Carrier Proteins/chemistry/genetics/*metabolism | 2 | 1.0 |
*Membrane Transport Proteins | 2 | 0.0 |
Antibodies/blood | 2 | 3.0 |
Blotting, Western | 13 | 0.0 |
Cholesterol, Dietary/pharmacology | 2 | 22.0 |
Lipoproteins/analysis | 2 | 8.0 |
Treatment Outcome | 8 | 0.0 |
Hyperlipidemia/epidemiology/*genetics | 3 | 60.0 |
Lipids/metabolism | 8 | 2.0 |
Mutation/genetics | 3 | 0.0 |
Severity of Illness Index | 3 | 0.0 |
Apolipoprotein A-I/metabolism | 7 | 9.0 |
Apolipoprotein A-II/metabolism | 3 | 21.0 |
Lipoproteins, HDL Cholesterol/*metabolism | 12 | 33.0 |
Pedigree | 10 | 0.0 |
Arteriosclerosis/*prevention & control | 2 | 11.0 |
*Cholesterol Esters | 2 | 100.0 |
Down-Regulation | 3 | 0.0 |
Electrochemistry | 3 | 3.0 |
Lipoproteins/blood/*chemistry | 3 | 50.0 |
Lipoproteins, HDL/chemistry | 2 | 22.0 |
Lipoproteins, LDL/chemistry | 2 | 20.0 |
Carrier Proteins/*physiology | 8 | 3.0 |
Esterification | 7 | 8.0 |
Dietary Fats, Unsaturated/*administration & dosage | 2 | 10.0 |
Apolipoproteins/metabolism | 5 | 12.0 |
Lipase/metabolism | 6 | 11.0 |
Phospholipids/blood | 13 | 9.0 |
Smoking/*metabolism | 2 | 4.0 |
Logistic Models | 2 | 0.0 |
Phenotype | 19 | 0.0 |
Cholesterol Esters/*genetics | 5 | 100.0 |
Placebos | 2 | 0.0 |
Alcohol Drinking | 3 | 2.0 |
Coronary Disease/*genetics | 4 | 6.0 |
*Deoxyribonucleases, Type II Site-Specific | 2 | 3.0 |
*Polymorphism, Restriction Fragment Length | 9 | 1.0 |
Cardiovascular Diseases/*genetics | 2 | 10.0 |
Pravastatin/therapeutic use | 2 | 12.0 |
European Continental Ancestry Group/genetics | 4 | 0.0 |
Lipoproteins, HDL Cholesterol/blood/*metabolism | 3 | 37.0 |
Liver/*metabolism | 7 | 1.0 |
Mesocricetus | 8 | 5.0 |
Carrier Proteins/analysis | 3 | 3.0 |
Lipoprotein Lipase/analysis | 2 | 18.0 |
Patient Compliance | 2 | 1.0 |
Adipocytes/*metabolism | 2 | 4.0 |
Receptors, LDL/metabolism | 6 | 6.0 |
Anticholesteremic Agents/*therapeutic use | 10 | 19.0 |
Apolipoproteins E/blood | 5 | 10.0 |
Electrophoresis, Polyacrylamide Gel | 24 | 0.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use | 4 | 8.0 |
Age Factors | 7 | 0.0 |
Electrophoresis, Gel, Two-Dimensional | 2 | 0.0 |
Hypercholesterolemia/blood | 3 | 15.0 |
Sex Factors | 8 | 0.0 |
3T3 Cells | 2 | 0.0 |
Carrier Proteins/biosynthesis/*genetics | 4 | 9.0 |
Genes, Reporter | 2 | 0.0 |
Electrostatics | 4 | 2.0 |
Fluorescence Polarization | 2 | 3.0 |
Glycosylation | 5 | 0.0 |
Hyperlipoproteinemia/*metabolism | 4 | 50.0 |
Lipoprotein Lipase/metabolism | 3 | 2.0 |
Lipoproteins/blood/chemistry | 2 | 18.0 |
Lipoproteins, VLDL/*blood | 4 | 5.0 |
Antibodies, Monoclonal/*immunology | 2 | 0.0 |
Carrier Proteins/*antagonists & inhibitors/blood/immunology | 2 | 100.0 |
Injections, Subcutaneous | 2 | 0.0 |
Insulin/*blood | 2 | 1.0 |
Lipolysis | 5 | 5.0 |
Sterol O-Acyltransferase/metabolism | 3 | 15.0 |
Antibody Specificity | 3 | 0.0 |
Circular Dichroism | 2 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Triglycerides/*metabolism | 10 | 11.0 |
Antibodies, Monoclonal | 11 | 0.0 |
Apolipoproteins/chemistry | 2 | 28.0 |
Protein Structure, Secondary | 3 | 0.0 |
Restriction Mapping | 3 | 0.0 |
Lipoproteins, VLDL/*metabolism | 2 | 2.0 |
Phosphatidylcholines/blood | 2 | 9.0 |
Protein Biosynthesis | 2 | 0.0 |
RNA, Messenger/*biosynthesis | 2 | 0.0 |
Lipoproteins, LDL/chemistry/*metabolism | 2 | 15.0 |
Receptors, LDL/*metabolism | 4 | 4.0 |
Follow-Up Studies | 4 | 0.0 |
Hypercholesterolemia, Familial/blood/*drug therapy | 4 | 28.0 |
Pravastatin/*therapeutic use | 6 | 42.0 |
Probucol/*therapeutic use | 7 | 58.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
Biological Markers/blood | 6 | 0.0 |
Hemoglobin A, Glycosylated/metabolism | 2 | 1.0 |
Carrier Proteins/*blood/immunology | 6 | 66.0 |
Reference Standards | 2 | 0.0 |
Arteriosclerosis/*genetics/metabolism | 2 | 33.0 |
*Genes, Structural | 2 | 0.0 |
Models, Genetic | 3 | 0.0 |
Point Mutation | 6 | 0.0 |
*RNA Splicing | 4 | 1.0 |
Lipoprotein Lipase/*blood | 7 | 6.0 |
Drug Combinations | 3 | 0.0 |
Fat Emulsions, Intravenous/pharmacology | 2 | 25.0 |
Infusions, Intravenous | 2 | 0.0 |
Lipoproteins, LDL/metabolism | 15 | 6.0 |
Membrane Proteins/*blood | 13 | 23.0 |
Europe | 2 | 0.0 |
*CCAAT-Enhancer-Binding Proteins | 2 | 1.0 |
Lipase/*metabolism | 6 | 10.0 |
Apolipoproteins B/genetics/*physiology | 2 | 66.0 |
Arteriosclerosis/prevention & control | 4 | 16.0 |
Hypercholesterolemia, Familial/*blood/*drug therapy | 2 | 66.0 |
Hyperlipidemia/blood/*etiology | 2 | 40.0 |
Serum Albumin/metabolism | 4 | 2.0 |
Carrier Proteins/*biosynthesis/*genetics | 2 | 8.0 |
Transgenes/*genetics | 2 | 6.0 |
Cholesterol/blood/metabolism | 2 | 10.0 |
Apolipoproteins/*metabolism | 3 | 7.0 |
In Vitro | 11 | 0.0 |
Apolipoproteins B/*blood | 5 | 3.0 |
Hyperlipoproteinemia/*blood | 4 | 16.0 |
Postprandial Period/*physiology | 3 | 9.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 2 | 1.0 |
Centrifugation, Density Gradient | 3 | 0.0 |
Perfusion | 2 | 0.0 |
Cloning, Molecular | 8 | 0.0 |
Dietary Fats/administration & dosage | 4 | 4.0 |
Fasting/*blood | 3 | 18.0 |
Hypercholesterolemia/*blood/drug therapy | 4 | 50.0 |
Hypertriglyceridemia/*blood | 3 | 7.0 |
Lipoprotein Lipase/*physiology | 2 | 11.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*physiology | 3 | 60.0 |
Fatty Acids, Nonesterified/metabolism | 2 | 6.0 |
*Body Composition | 2 | 1.0 |
Cross-Sectional Studies | 3 | 0.0 |
Hypercholesterolemia | 2 | 50.0 |
Arteriosclerosis/metabolism | 2 | 3.0 |
Glycoproteins/blood | 8 | 14.0 |
Cattle | 3 | 0.0 |
Coronary Disease/etiology | 3 | 8.0 |
Carrier Proteins/*analysis | 4 | 4.0 |
Estrogens/*physiology | 2 | 5.0 |
Diabetes Mellitus, Type 2/*blood | 6 | 5.0 |
Fatty Acids, Nonesterified/blood | 6 | 3.0 |
*Insulin Resistance | 2 | 1.0 |
Lipase/*blood | 9 | 14.0 |
Smoking/*blood | 4 | 16.0 |
Alcohol Drinking/*blood | 3 | 21.0 |
Cholesterol, Dietary/administration & dosage | 2 | 7.0 |
Crosses, Genetic | 3 | 0.0 |
Arteriosclerosis | 2 | 25.0 |
Probucol/*pharmacology | 2 | 22.0 |
RNA, Messenger/*analysis | 3 | 0.0 |
Biological Transport/physiology | 5 | 3.0 |
Adipose Tissue/cytology/*metabolism | 3 | 20.0 |
Osmolar Concentration | 3 | 0.0 |
RNA, Messenger/*metabolism | 4 | 0.0 |
Odds Ratio | 2 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
Thyrotropin/blood | 2 | 0.0 |
Thyroxine/blood/therapeutic use | 2 | 13.0 |
Macrophages, Peritoneal/*metabolism | 2 | 9.0 |
Apolipoprotein A-I/analysis | 4 | 21.0 |
Lipoproteins, HDL/*blood/chemistry | 4 | 36.0 |
Apolipoprotein A-I/genetics | 5 | 25.0 |
Apolipoproteins A/genetics | 2 | 12.0 |
*Chromosome Mapping | 2 | 0.0 |
Chromosomes, Human, Pair 16 | 3 | 2.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/genetics | 2 | 18.0 |
Receptors, LDL/genetics | 3 | 4.0 |
Apolipoprotein A-I/*blood | 6 | 18.0 |
Apolipoproteins E/*blood | 3 | 5.0 |
Blood Glucose/analysis | 2 | 0.0 |
Bezafibrate/*therapeutic use | 2 | 14.0 |
Gemfibrozil/*therapeutic use | 2 | 8.0 |
Carrier Proteins/*genetics/*metabolism | 3 | 3.0 |
Coronary Disease/blood | 4 | 14.0 |
Enzyme-Linked Immunosorbent Assay/methods | 3 | 1.0 |
Spectrometry, Fluorescence | 3 | 0.0 |
*Gene Expression | 2 | 0.0 |
Microscopy, Electron | 4 | 0.0 |
Antibodies | 2 | 0.0 |
CHO Cells/metabolism | 2 | 5.0 |
Reproducibility of Results | 2 | 0.0 |
Lipoproteins, HDL/*physiology | 3 | 30.0 |
Apolipoproteins B/*genetics | 2 | 1.0 |
Lipoproteins | 2 | 33.0 |
Hypercholesterolemia/blood/drug therapy | 2 | 50.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Administration, Oral | 5 | 0.0 |
Heparin/pharmacology | 3 | 1.0 |
Apolipoprotein A-I/*metabolism | 5 | 11.0 |
Glycine/genetics | 2 | 2.0 |
Lipoproteins, HDL/*chemistry/*metabolism | 2 | 40.0 |
Swine | 3 | 0.0 |
*Exons | 4 | 1.0 |
Carrier Proteins/*chemistry | 4 | 6.0 |
Cholesterol Esters/chemistry | 3 | 60.0 |
Apolipoprotein A-I/chemistry | 2 | 25.0 |
Binding, Competitive | 6 | 0.0 |
Oleic Acid/*pharmacology | 2 | 22.0 |
Lipoproteins/*blood/chemistry | 2 | 16.0 |
Lipoproteins, HDL Cholesterol/blood/metabolism | 2 | 25.0 |
Biological Transport/drug effects | 4 | 1.0 |
Fatty Acids, Nonesterified/blood/*physiology | 2 | 50.0 |
Palmitic Acid/pharmacology | 2 | 50.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Biological Markers | 3 | 0.0 |
Carrier Proteins/physiology | 2 | 1.0 |
Dietary Carbohydrates/administration & dosage | 2 | 7.0 |
Apolipoproteins A/blood/*genetics | 2 | 16.0 |
Energy Metabolism | 2 | 1.0 |
Fatty Acids/blood | 2 | 4.0 |
Fatty Acids, Nonesterified/*blood | 4 | 8.0 |
*Acute-Phase Proteins | 2 | 1.0 |
*Membrane Glycoproteins | 2 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Cholesterol Esters | 2 | 40.0 |
Erythrocytes/metabolism | 3 | 1.0 |
Lipoproteins/blood/*metabolism | 2 | 6.0 |
Alternative Splicing | 2 | 0.0 |
Introns | 3 | 0.0 |
*Cloning, Molecular | 4 | 1.0 |
DNA, Complementary/*genetics | 2 | 0.0 |
Recombinant Proteins | 3 | 0.0 |
Carrier Proteins/blood/genetics/*metabolism | 4 | 57.0 |
Hyperlipoproteinemia/*blood/genetics | 2 | 50.0 |
Lipid Metabolism, Inborn Errors/genetics/metabolism | 2 | 100.0 |
Exons | 4 | 0.0 |
Anticholesteremic Agents/*pharmacology | 3 | 10.0 |
Lipoproteins, HDL/*blood/classification | 4 | 36.0 |
Anticholesteremic Agents/pharmacology/*therapeutic use | 2 | 66.0 |
Molecular Weight | 16 | 0.0 |
Drug Administration Schedule | 3 | 0.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Hyperlipidemia/blood | 2 | 5.0 |
Carrier Proteins/blood/*immunology | 2 | 66.0 |
Epitope Mapping | 2 | 0.0 |
Immunoblotting | 4 | 0.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Infant | 2 | 0.0 |
Lipoproteins, HDL Cholesterol/*blood/genetics | 2 | 25.0 |
Apolipoproteins A/*blood | 3 | 6.0 |
Blood Pressure | 3 | 0.0 |
Cholesterol, Dietary/*pharmacology | 2 | 14.0 |
Liver/drug effects/*metabolism | 2 | 2.0 |
Transgenes | 2 | 0.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | 4 | 12.0 |
Single-Blind Method | 4 | 1.0 |
Apolipoprotein A-I/pharmacology | 2 | 20.0 |
Carrier Proteins/drug effects/*metabolism | 3 | 23.0 |
Lipopolysaccharides/*pharmacology | 2 | 0.0 |
Lipoproteins, HDL | 2 | 25.0 |
Peptides/pharmacology | 2 | 1.0 |
Chromatography, Affinity | 3 | 0.0 |
Coronary Angiography | 3 | 1.0 |
Apolipoprotein A-II/*blood | 2 | 33.0 |
Fatty Acids, Unsaturated/administration & dosage | 2 | 50.0 |
Diabetes Mellitus/metabolism | 2 | 5.0 |
Sterol O-Acyltransferase/*blood | 2 | 25.0 |
Carrier Proteins/*immunology | 2 | 4.0 |
Deoxyribonucleases, Type II Site-Specific/metabolism | 4 | 2.0 |
Hyperlipoproteinemia/*genetics | 2 | 18.0 |
*Introns | 2 | 0.0 |
Blood Protein Electrophoresis | 2 | 1.0 |
Glycoproteins/*deficiency | 3 | 60.0 |
Alcoholism/*blood | 4 | 25.0 |
DNA/*analysis | 2 | 0.0 |
Nuclear Family | 3 | 1.0 |
Alcohol Drinking/metabolism | 2 | 25.0 |
Exercise/physiology | 2 | 3.0 |
Smoking/metabolism | 2 | 3.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
Carrier Proteins/*genetics/physiology | 2 | 5.0 |
Apolipoproteins A/blood | 5 | 7.0 |
Carrier Proteins/*pharmacology | 2 | 4.0 |
Apolipoprotein A-I/*biosynthesis/blood/genetics | 2 | 100.0 |
Carrier Proteins/*biosynthesis/blood/genetics | 2 | 100.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Lipoproteins, VLDL Cholesterol/*blood | 3 | 42.0 |
Carrier Proteins/genetics/*secretion | 2 | 100.0 |
Cholesterol/*pharmacology | 2 | 10.0 |
Lipoproteins, LDL/pharmacology | 2 | 4.0 |
Molecular Probes | 2 | 3.0 |
Phosphatidylcholines/*metabolism | 2 | 4.0 |
Diabetes Mellitus, Type 2/*metabolism | 2 | 4.0 |
Phospholipids/*metabolism | 2 | 1.0 |
Culture Media, Conditioned | 2 | 0.0 |
Adipose Tissue/*metabolism | 2 | 1.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Omentum | 2 | 12.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Chromatography, Thin Layer | 2 | 1.0 |
Hemoglobin A, Glycosylated/analysis | 2 | 0.0 |
Ethanol/*pharmacology | 2 | 1.0 |
Apolipoproteins B/*metabolism | 2 | 2.0 |
Arteriosclerosis/etiology | 5 | 7.0 |
*Gene Expression Regulation | 5 | 0.0 |
Mice, Inbred CBA | 3 | 0.0 |
Hela Cells | 2 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Chromatography, Affinity/methods | 3 | 4.0 |
Gemfibrozil/administration & dosage/*therapeutic use | 2 | 100.0 |
Hyperlipoproteinemia/*blood/complications | 2 | 100.0 |
Hypercholesterolemia, Familial/*blood | 3 | 17.0 |
Fluorescent Dyes | 3 | 0.0 |
*Spectrometry, Fluorescence | 2 | 33.0 |
Apolipoproteins/genetics/metabolism | 2 | 50.0 |
Liposomes | 2 | 0.0 |
Apolipoproteins/analysis | 5 | 18.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Genes, Dominant | 2 | 0.0 |
Phosphatidylcholines/metabolism | 2 | 2.0 |
Diabetes Mellitus/*metabolism | 2 | 5.0 |
Macaca fascicularis | 3 | 1.0 |
Radioimmunoassay | 6 | 0.0 |
Lipoproteins, HDL/blood/*genetics | 3 | 50.0 |
Hypercholesterolemia/*drug therapy | 2 | 18.0 |
Carrier Proteins/*blood/chemistry/genetics | 2 | 100.0 |
Carrier Proteins/*blood/isolation & purification | 2 | 40.0 |
RNA Splicing | 2 | 0.0 |
Hypertriglyceridemia/*metabolism | 3 | 25.0 |
DNA/analysis | 4 | 0.0 |
Genetic Markers | 2 | 0.0 |
Predictive Value of Tests | 3 | 0.0 |
Coronary Arteriosclerosis/*blood | 2 | 14.0 |
Macrophages/*metabolism | 3 | 1.0 |
Lipoproteins/*physiology | 2 | 16.0 |
Neutralization Tests | 2 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel/methods | 2 | 1.0 |
*Heterozygote | 2 | 0.0 |
Cholesterol/blood/*metabolism | 2 | 9.0 |
Apolipoprotein A-I/*chemistry | 2 | 25.0 |
Apolipoprotein A-II/*pharmacology | 2 | 50.0 |
Apolipoproteins E/analysis | 3 | 18.0 |
Coronary Disease/prevention & control | 3 | 30.0 |
Apolipoproteins/*analysis | 3 | 18.0 |
Carrier Proteins/chemistry | 2 | 5.0 |
Lipoproteins, LDL/blood/*chemistry | 2 | 25.0 |
*Antibodies, Monoclonal | 3 | 1.0 |
Epitopes/immunology | 3 | 0.0 |
Oleic Acid | 4 | 6.0 |
Emigration and Immigration | 2 | 4.0 |
Greece/ethnology | 2 | 10.0 |
Italy/ethnology | 2 | 5.0 |
Lipoproteins, HDL/*blood/isolation & purification | 2 | 20.0 |
Hypertriglyceridemia/blood | 2 | 8.0 |
Pregnancy/*blood | 2 | 1.0 |
Pregnancy Trimester, Third | 2 | 1.0 |
Iodine Radioisotopes | 2 | 0.0 |
Glycoproteins/*antagonists & inhibitors | 2 | 40.0 |
Lipoproteins, LDL/*blood/chemistry | 2 | 10.0 |
Immunoglobulin G | 2 | 1.0 |
Introns/*genetics | 2 | 1.0 |
Oleic Acids/*pharmacology | 4 | 26.0 |
Genes, Structural | 3 | 0.0 |
Lipoproteins, HDL Cholesterol/blood/genetics | 2 | 15.0 |
Precipitin Tests | 2 | 0.0 |
Radioimmunoassay/methods | 2 | 1.0 |
Albumins/pharmacology | 2 | 22.0 |
Fatty Acids, Nonesterified/*metabolism | 3 | 11.0 |
Glycoproteins/blood/genetics/*metabolism | 3 | 100.0 |
Lipoproteins, HDL/*metabolism/ultrastructure | 2 | 66.0 |
Lipoproteins, LDL Cholesterol/metabolism | 4 | 11.0 |
Carrier Proteins/pharmacology | 3 | 4.0 |
Carrier Proteins | 2 | 3.0 |
Rats, Inbred Strains | 2 | 0.0 |
Oleic Acids/metabolism | 2 | 9.0 |
Apolipoprotein A-I | 3 | 2.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
*Oleic Acid | 2 | 66.0 |
Carrier Proteins/metabolism/*physiology | 2 | 5.0 |
Liver/drug effects/metabolism | 2 | 2.0 |
Lipase/*pharmacology | 2 | 66.0 |
Substrate Specificity | 2 | 0.0 |
Lipids/blood/*genetics | 2 | 40.0 |
Smoking/adverse effects | 2 | 0.0 |
Antibodies, Monoclonal/*physiology | 2 | 5.0 |
DNA/*genetics | 2 | 0.0 |
Longevity/*genetics | 2 | 5.0 |
Twins, Monozygotic | 2 | 2.0 |
Membrane Proteins/blood/metabolism | 2 | 50.0 |
*Food | 2 | 2.0 |
Oligonucleotides, Antisense/pharmacology | 2 | 0.0 |
Genetic Markers/genetics | 2 | 0.0 |
Polymorphism, Single Nucleotide/*genetics | 2 | 0.0 |
Aniline Compounds/*chemical synthesis/pharmacokinetics/pharmacology | 2 | 100.0 |
Environment | 2 | 2.0 |
Coronary Disease/epidemiology | 2 | 10.0 |
Estrogen Replacement Therapy | 2 | 4.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Pharmacogenetics/*methods | 2 | 11.0 |
